Acorda Therapeutics Inc (ACOR)

20.30
NASDAQ : Health Care
Prev Close 20.25
Day Low/High 19.85 / 20.50
52 Wk Low/High 16.40 / 43.63
Avg Volume 675.10K
Exchange NASDAQ
Shares Outstanding 46.11M
Market Cap 933.81M
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acorda Stroke Study Fails, Dampening Revenue Growth Plans

Acorda Stroke Study Fails, Dampening Revenue Growth Plans

A mid-stage study of Ampyra in patients with walking difficulties following a stroke "did not show sufficient efficacy" to support further clinical development, Acorda said Monday.

Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties

Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the MILESTONE clinical study did not show sufficient efficacy to support further development of dalfampridine to improve post-stroke walking difficulties (PSWD).

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Acorda Therapeutics To Present At The Stifel 2016 Healthcare Conference

Acorda Therapeutics To Present At The Stifel 2016 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.

Acorda Provides Financial And Pipeline Update For Third Quarter 2016

Acorda Provides Financial And Pipeline Update For Third Quarter 2016

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2016.

Commit To Purchase Acorda Therapeutics At $7, Earn 15.4% Annualized Using Options

Commit To Purchase Acorda Therapeutics At $7, Earn 15.4% Annualized Using Options

Investors eyeing a purchase of Acorda Therapeutics Inc shares, but tentative about paying the going market price of $19.75/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2017 put at the $7 strike, which has a bid at the time of this writing of 55 cents.

Acorda To Host Conference Call To Discuss Third Quarter 2016 On October 27, 2016

Acorda To Host Conference Call To Discuss Third Quarter 2016 On October 27, 2016

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2016 financial results and pipeline updates on Thursday, October 27 at 8:30 a.

Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine

Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine

Results from Phase 1, Phase 2a and preclinical studies of CVT-301, an inhaled form of levodopa, have been featured in the current edition of Science Translational Medicine.

Acorda Therapeutics, Inc. Has Been Named As One Of The 100 Best Medium Workplaces Based On An Independent Survey By Fortune Magazine And Great Place To Work®. (Photo: Business Wire)

Acorda Therapeutics, Inc. Has Been Named As One Of The 100 Best Medium Workplaces Based On An Independent Survey By Fortune Magazine And Great Place To Work®. (Photo: Business Wire)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the 100 Best Medium Workplaces based on an independent survey by  Fortune  Magazine and Great Place to Work ®.

Acorda Announces Departure Of Michael Rogers

Acorda Announces Departure Of Michael Rogers

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Chief Financial Officer Michael Rogers has left the company.

Oversold Conditions For Acorda Therapeutics (ACOR)

Oversold Conditions For Acorda Therapeutics (ACOR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

(Graphic: Business Wire)

(Graphic: Business Wire)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced it has launched a new community resource for people with Parkinson's, " The Many Faces of OFFSM 1" Facebook page.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCC, CYS, DISH, ESRT, FCFS, FSI, GIMO, INVA, KSU, NATI, ORC, RMCF, TREE, WLDN, WMGI, WRE, ZION Downgrades: ACIW, ACOR, BSX, DLR, FI, HTH, IP, OVBC, SBBX Initiations: GNRT, MB, PUB Read on to get TheStreet Quant Ratings' detailed report:

Acorda Provides Financial And Pipeline Update For Second Quarter 2016

Acorda Provides Financial And Pipeline Update For Second Quarter 2016

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the second quarter ended June 30, 2016.

Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's

Trade-Ideas: Acorda Therapeutics (ACOR) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: Acorda Therapeutics (ACOR)

Strong On High Volume: Acorda Therapeutics (ACOR)

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a strong on high relative volume candidate

September 16th Options Now Available For Acorda Therapeutics (ACOR)

September 16th Options Now Available For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading today, for the September 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new September 16th contracts and identified one put and one call contract of particular interest.

Acorda To Host Conference Call To Discuss Second Quarter 2016 On July 28, 2016

Acorda To Host Conference Call To Discuss Second Quarter 2016 On July 28, 2016

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2016 financial results and pipeline updates on Thursday, July 28 at 8:30 a.

Acorda Appoints Burkhard Blank, M.D., As Chief Medical Officer (CMO)

Acorda Appoints Burkhard Blank, M.D., As Chief Medical Officer (CMO)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Burkhard Blank, M.

Biotie Therapies Corp. Announces That The Delisting Of Its American Depositary Shares From NASDAQ Global Select Market Has Become Effective

Biotie Therapies Corp. Announces That The Delisting Of Its American Depositary Shares From NASDAQ Global Select Market Has Become Effective

Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (" Biotie" or the " Company") announces that the voluntary delisting of its American Depositary Shares (" ADSs") from the NASDAQ Global Select Market (" Nasdaq US") became...

Acorda Presents Phase 1 Data On CVT-427 For Acute Treatment Of Migraine At 58th Annual Scientific Meeting Of The American Headache Society

Acorda Presents Phase 1 Data On CVT-427 For Acute Treatment Of Migraine At 58th Annual Scientific Meeting Of The American Headache Society

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption...

Acorda Therapeutics To Present At The 37th Annual Goldman Sachs Global Healthcare Conference

Acorda Therapeutics To Present At The 37th Annual Goldman Sachs Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).

Acorda To Discontinue Development Of PLUMIAZ For Treatment Of Epilepsy Seizure Clusters

Acorda To Discontinue Development Of PLUMIAZ For Treatment Of Epilepsy Seizure Clusters

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ TM (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people...

Biotie Therapies Corp. To Delist Its American Depositary Shares From The Nasdaq Global Select Market

Biotie Therapies Corp. To Delist Its American Depositary Shares From The Nasdaq Global Select Market

Biotie Therapies Corp. ("Biotie") today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs"), each representing 80 Biotie ordinary shares with no nominal value...

Acorda Therapeutics Named One Of The Best Places To Work For In New York

Acorda Therapeutics Named One Of The Best Places To Work For In New York

Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG).

Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock

Acorda Therapeutics (ACOR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate

Acorda Therapeutics (ACOR) Is Today's Dead Cat Bounce Stock

Acorda Therapeutics (ACOR) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "dead cat bounce" (down big yesterday but up big today) candidate